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ABSTRACT
The compatibility of propofol MCT/LCT with non-PVC soft bag was investigated in this study. Solutions of 2.0 and 2.5 mg/mL
propofol MCT/LCT in 0.9% NaCl solution were filled into CRYOVAC® containers. The studied samples were grouped and stored at
ambient temperature (25 ± 2°C) in the light, at ambient temperature in the dark, and at 2-8°C in the dark for 5 days. At indicated sampling
time, propofol was assayed by high-performance liquid chromatography. For long-term study, propofol samples were analyzed at day 8
and at day 15. The results showed that all studied samples were stable for 5 days. Propofol contents decreased by 8-12% and 15-23%
when stored in the non-PVC bag at ambient temperature in the light for 8 days and 15 days, respectively. Studied samples in non-PVC bag
stored at ambient temperature in the dark showed 3-9% decrease when stored for 8 days, whereas 10-13% decrease for 15 days. Propofol
concentration in non-PVC bag stored at 2-8°C in the dark showed approximately 2-8% decrease at both day 8 and day 15. In conclusion,
the 2.0 and 2.5 mg/mL propofol MCT/LCT in 0.9% NaCl solution with CRYOVAC® container stored at all conditions were stable for
5 days. It is found that samples stored at ambient temperature were more labile as compared to those at 2-8°C; moreover, propofol sample
was vulnerable to light exposure. In addition, DEHP additive was not detected in the CRYOVAC® soft bag container by HPLC with a
quantitation limit at 5 ppm. Therefore, CRYOVAC® non-PVC soft bag is a suitable container system for propofol MCT/LCT emulsion.
Key words: compatibility, propofol MCT/LCT, non-PVC soft bag containers

INTRODUCTION
As a common and safe anesthetic agent, propofol
provides fast onset, deep sedation, rapid cognition and functional recovery. However, pain on injection is a major disadvantage with approximately 70% reported incidence when a
standard emulsion formulation of propofol is administered
with no intervention to reduce pain(1). In addition to opioids
or metoclopromide, one of the most frequently used method
for pain management is the administration of lignocaine, a
kinin cascade stabilizer(2), either before propofol injection,
with or without a tourniquet(3) or added to the propofol emulsion as a premixture(1,4,5).
It is found that the amount of free propofol would result
in injection pain in the aqueous phase of the emulsion. Efforts
have been made to reduce propofol content in the aqueous
phase. A new formulation of propofol has been demonstrated
* Author for correspondence. Tel: +886-3-5983811 ext. 210;
Fax: +886-3-5982855; E-mail: pearl@cscp.com.tw
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to ease the incidence of mild pain in 1997(6). The new formulation of propofol contains equal proportions (50 : 50) of
medium chain triglycerides (MCT) and long chain triglycerides (LCT), which was found to cause less pain on injection
compared with standard propofol LCT.
Despite the successful development of emulsion formulation, propofol MCT/LCT is incompatible with PVC bags.
The plastic additive, di-(2-ethylhexyl)phthalate (DEHP), was
extractable in MCT/LCT formulation. Accordingly, glass
vial, polypropylene bottles, and polyolefin bags were recommended(7,8,9). To explore other container system, multi-layer
structure plastic containers are attractive because plastic is
flexible, and will collapse when the contents are drawn off,
which means less space required and lower waste disposal
costs.
CRYOVAC® containers are hot-formed by the blowfill-seal process; no additive is used during the manufacturing. Moreover, the material contains little particulate
contamination than glass or PVC, and does not contain any
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additives that are liable to migrate into the drug solutions.
Risk of leachables and particulate issues are low. Therefore,
we aimed to study the feasibility to use CRYOVAC® as a
container closure system for propofol MCT/LCT emulsion.
For clinical dosing purpose, solutions containing 2.0 2.5 mg/mL of propofol MCT/LCT (in 5% glucose solution)
are generally prepared and proven chemically and physically
stable for 24 h at 25°C. In the present study, we investigated
the compatibility of propofol MCT/LCT in 0.9% NaCl solution with the non-PVC CRYOVAC® containers. We studied
the stability of the solutions stored under three different light
and temperature conditions to evaluate whether solutions of
2.0 and 2.5 mg/mL propofol MCT/LCT in 0.9% NaCl solution could be prepared in advance.

MATERIALS AND METHODS
I. Study Drug
Propofol MCT/LCT was supplied by Chi Sheng Chemical Corporation (CSCC) as an injectable solution in 20 mL
Ampule (10 mg/mL).
II. Solvent for Dilution and Containers
The 0.9% NaCl solution (Chi Sheng Chemical Corporation Medical) used to dilute the propofol MCT/LCT was
supplied in CRYOVAC® polyolefins soft bag container
(Sealed Air) and in glass bottle (Chi Sheng Chemical Corporation Medical).
III. Study Design
Two concentrations of propofol, i.e. 2.0 and 2.5 mg/mL,
in MCT/LCT emulsion, which is commonly used in clinical practice, were prepared in this study. To prepare the
2.0 mg/mL solution, a total of 5 Ampule bottles, or 100 mL
propofol MCT/LCT, were added to 400 mL 0.9% NaCl solution; for the preparation of the 2.5 mg/mL solution, 5 Ampule
bottles (100 mL) of propofol MCT/LCT were added to 300
mL 0.9% NaCl solution. The dilutions were conducted under
a laminar flow hood. Besides, the glass vial served as a
control, since the compatibility of propofol MCT/LCT with
glass has been established(10).
The solutions of propofol MCT/LCT in glass or
CRYOVAC® non-PVC soft bag containers were stored under
three different conditions: (I) at ambient temperature (25 ±
2°C) and in ambient light (daylight, out of direct sunlight,
on a bench in the middle of the laboratory); (II) at ambient
temperature in the dark (wrapped in aluminum foil); and
(III) at 2-8°C in the dark (in a refrigerator). These conditions
are those any diluted drug solution is liable to encounter in
clinical practice before administrated to a patient. For each
storage condition the study samples in CRYOVAC® were
made in triplicate. A single glass control was prepared. The
study design is listed in Table 1. The supplier recommends

!21卷1期書冊.indb 88

that diluted solutions of propofol MCT/LCT should not be
frozen because of an increased risk of the emulsion liable to
break up at low temperatures.
For each preparation, the first sample was taken immediately after dilution and bottling (sampling time T0), which
served as the baseline. Subsequent samples were taken at the
following times; on day 1 after 1-, 2-, 4-, 6-h storage, and then
every day for 4 days (i.e. day-2, day-3, day-4, and day-5).
For long term stability study, propofol MCT/LCT emulsion in
0.9% NaCl solution was sampled on day 8 and day 15.
IV. Analytical Methods
At each sampling time, the apperance was examined by
visual inspection and the samples were analyzed by HPLC.
First, the studied sample was transferred to a clear glass tube
for visual inspection. The samples were examined against a
white background and a black background under unpolarized
light. The appearance of sample should be clear, contain no
yellow oil drop and conform with a uniform phase.
For HPLC assay, sample was diluted with isopropanol
(Macron, USA) and filtered using a 25 mm syringe filter
with 0.45 μm PVDF membrance (Pall Corporation, USA).
If any yellow oil drops were observed in visual inspection, the sample was shaked vigorously before diluted with
isopropanol.
Propofol sample was loaded on a pentafluorophenyltype stationary column (Interchim, 250 × 4.6 mm i.d., 5 μm).
The mobile phase was a mixture (75/25, v/v) of acetonitrile
(Panreac, SPAIN) and purified water (CSCC, Taiwan). The
isocratic flow rate was 1 mL/min. The detection wavelength
was set at 275 nm. An HPLC system (Alliance 2695, Waters)
equipped with a photodiode detector (PDA 2996, Waters)
was used in this study. Chromatograms were processed using
Empower 2.
The standard solutions were prepared by dilution of
2 mg/mL propofol (U.S. Pharmacopeia reference standard,
ROCKVILLE, MD, USA.) in isopropanolol (v/v). The
concentrations of propofol standard are 0, 0.4, 0.6, 0.8, 1.0,
and 1.2 mg/mL. These solutions were used to plot a calibration line with regression equation y = ax + b (where x is the
propofol concentration and y is the area under the propofol
peak).
The propofol assay method, we used 0.8 mg/mL of
USP propofol to confirm chromatographic system suitability
including column efficiency: more than 1000 theoretical
plates; tailing factor less than 1.5 for the propofol peak and
relative standard deviation not more than 2% for the replicate
injection. Precision, expressed as a relative standard deviation, was 0.24 and 0.5% for intra-day assay variability (n =
6) and for inter-day variability (n = 6), respectively. Method
linearity was in the range from 0.4 to 1.2 mg/mL with a
correlation coefficient r2 = 0.9999. The equation for the
mean calibration was y = 5.4467．106x + 8.8397．104. The
recovery of propofol from propofol MCT/LCT was 98.53 ±
0.11%(11). The chromatographic method was able to detect
and separate propofol from any degradation products such as
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3,3’-5,5’- tetraisopropyldiphenol and 2,6-diisopropylbenzoquinone. The HPLC method was validated as a stability-indicating method for propofol MCT/LCT emulsion. It provided
specific quantitation of the drug itself without interference by
any of its breakdown products and its formulation(11).
The average concentrations of propofol in study samples
stored in CRYOVAC® were calculated from triplicate tests.
The results are expressed in percentages relative to the initial
concentration at T0 (value taken as 100%). Drug solutions are
considered acceptable for use if the content is not less than
90% of the label claim(9).
V. Chromatographic Analysis of DEHP
Solutions of 2.0 and 2.5 mg/mL propofol MCT/LCT
were filled into CRYOVAC® containers in three storage
conditions for 15 days. Ten milliliter of the samples were
extracted once with 10 mL of hexane. Then, direct injection
of 20 μL the solvent extract was performed. All the measurements were performed in triplicate(12). The column was a
LICHROSPHER 100 RP18 endcapped (Merck). The mobile
phase was a mixture of acetonitrile-water (95/5, v/v). The
flow was isocratic at a flow rate of 1 mL/min. The detection
wavelength was 224 nm. The standard DEHP was supplied
by Chem Service, Inc. (Pennsylvania, USA).

RESULTS AND DISCUSSION
I. Appearance of Study Samples
The CRYOVAC® soft bags contained propofol samples,
either 2.0 or 2.5 mg/mL, were stored at conditions listed in
Table 1. All samples stored for 5 days showed no yellow oil
drop and remained uniform phases as shown in Table 2 and
3. This result suggested the physical property of propofol

MCT/LCT in 0.9% NaCl emulsion is stable for 5 days when
stored at CRYOVAC® non-PVC soft bag.
II. Concentration Changes of Propofol in Study Samples
The propofol content was assayed by HPLC method.
At each sampling time, three studied samples in soft bags
and one control sample in glass vial were assayed. Table 2
showed that control propofol samples diluted to 2.5 mg/mL
in 0.9% NaCl solution stored under all conditions were stable
for 5 days in glass vial. For studied samples stored at ambient
temperature and light condition, propofol content showed
an 8% decrease, i.e. from 99 to 92%. When studied sample
stored in the dark and at ambient temperature, propofol
content changed from 100 to 94%. The same 6% decrease was
observed when samples were stored in the dark and at 2-8°C,
indicating that light exposure had little impact on propofol
content. Of particularly noteworthy is the propofol contents
for all study samples stored in CRYOVAC® non-PVC soft
bags for 6 h did not change. The contents of studied samples
started to decrease slowly from day 2.
The content analysis of propofol at 2.0 mg/mL was listed
in Table 3. The control group showed the determined content
was in the range from 96 to 98%. For studied samples stored
at ambient temperature and light condition, propofol contents
decreased from 100 to 92%, whereas 100 to 95% for study
sample in the dark and at ambient temperature. When samples
were stored in the dark and at 2-8°C, the determined contents
were in the range from 100 to 97%. It was observed that all
studied samples in this group were very stable for 6 hours, as
indicated for 2.5 mg/mL studied group. An obvious decrease
was detected when propofol was sampled at day 2, especially
for samples stored at ambient temperature and light condition.
The most striking changes were samples stored at ambient
temperature and light condition, and both 2.5 and 2.0 mg/mL
of propofol content decreased by 8%. For other groups as

Table 1. Experimental conditions
Container
CRYOVAC®

Concentration of propofol MCT/LCT

2.0 mg/mL

2.5 mg/mL

Glass

2.0 mg/mL

2.5 mg/mL
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Condition of storage

Number of preparations

Ambient light and temperature

3

Dark and ambient temperature

3

Dark and at 2-8°C

3

Ambient light and temperature

3

Dark and ambient temperature

3

Dark and at 2-8°C

3

Ambient light and temperature

1

Dark and ambient temperature

1

Dark and at 2-8°C

1

Ambient light and temperature

1

Dark and ambient temperature

1

Dark and at 2-8°C

1

2013/3/19 下午 03:47:38

90
Journal of Food and Drug Analysis, Vol. 21, No. 1, 2013

Table 2. Stability of solution of 2.5 mg/mL of propofol MCT/LCT in 0.9% NaCl solution

Initial concentration (mg/mL)

Ambient light and temperature

Dark and ambient temperature

®

®

Glass

CRYOVAC

Glass

CRYOVAC

(n = 1)

(n = 3)

(n = 1)

(n = 3)

0.90

0.921 ± 0.001

0.90

0.922 ± 0.002

Dark and at 2-8°C
Glass

CRYOVAC®

(n = 1)

(n = 3)

0.898

0.922 ± 0.001

Percent initial concentration remaining after storage (mean ± S.D.)
D1(1h)

99.33

99.89 ± 0.06

99.33

100.00 ± 0.11

99.44

99.78 ± 0.06

D1(2h)

100.44

99.68 ± 0.22

99.89

100.00 ± 0.17

100.00

99.35 ± 0.17

D1(4h)

99.67

98.59 ± 0.13

99.78

99.35 ± 0.06

99.55

99.13 ± 0.19

D1(6h)

98.67

98.37 ± 0.17

99.67

98.59 ± 0.17

98.66

98.92 ± 0.23

D2

99.78

96.10 ± 0.00

99.89

96.74 ± 0.06

99.11

97.61 ± 0.00

D3

99.89

94.79 ± 0.63

95.89

96.63 ± 0.11

96.44

96.42 ± 0.11

D4

99.22

92.52 ± 0.11

99.00

94.25 ± 0.06

100.00

95.66 ± 0.00

D5
Appearance (D5)

99.89

92.08 ± 0.17

99.00

94.35 ± 0.11

100.22

94.25 ± 0.06

White uniform

White uniform

White uniform

White uniform

White uniform

White uniform

Table 3. Stability of solution of 2.0 mg/mL of propofol MCT/LCT in 0.9% NaCl solution
Ambient light and temperature
Glass
(n = 1)
Initial concentration (mg/mL)

0.758

Dark and ambient temperature

CRYOVAC®

Glass

(n = 3)

(n = 1)

0.76 ± 0.01

0.759

Dark and at 2-8°C

CRYOVAC®

Glass

(n = 3)

(n = 1)

(n = 3)

0.758

0.759 ± 0.01

0.76 ± 0.01

CRYOVAC®

Percent initial concentration remaining after storage (mean ± SD)
D1(1h)

98.02

100.26 ± 0.08

96.97

99.87 ± 0.26

96.70

100.00 ± 0.13

D1(2h)

96.83

99.47 ± 0.20

96.31

99.87 ± 0.13

96.83

99.34 ± 0.08

D1(4h)

97.23

99.08 ± 0.08

96.05

99.21 ± 0.20

96.70

99.21 ± 0.08

D1(6h)

97.63

98.56 ± 0.02

96.71

98.55 ± 0.22

96.97

99.74 ± 0.15

D2

96.44

96.58 ± 0.08

96.18

97.50 ± 0.50

97.89

98.68 ± 0.08

D3

95.78

96.18 ± 0.13

95.52

97.37 ± 0.08

97.10

97.76 ± 0.00

D4

96.31

95.79 ± 0.35

97.10

97.24 ± 0.08

97.49

97.37 ± 0.26

D5

96.04

92.63 ± 0.20

96.84

95.00 ± 0.53

97.89

96.97 ± 0.13

Appearance (D5)

White uniform

White uniform

well as control groups, the changes were insignificant. The
specification set for propofol drug content is not less than
90%. Accordingly, both 2.5 and 2.0 mg/mL of propofol in
0.9% NaCl solution were stable for 5 days.
III. Long Term Stability of Propofol Emulsion in 0.9% NaCl
Solution
To understand the long term stability of propofol MCT/
LCT emulsion in 0.9% NaCl, samples were analyzed at 8th
day and at 15th day. Table 4 summarized the studied results.
The control group in glass vial exhibited uniform solution
phase and contained no yellow oil drop as shown in Table
4. The determined contents were in the range from 95 to
100%. This result indicated that the propofol MCT/LCT
emulsion in 0.9% NaCl was very stable in glass vial for 2
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White uniform

White uniform

White uniform

White uniform

weeks. For studied samples stored within CRYOVAC® at
ambient temperature and under light condition for 8 days,
the samples went opalenscence and developed small oil drop.
After shaking to remix, about 10% decrease in content was
detected by HPLC for both 2.5 and 2.0 mg/mL groups. For
samples under condtion II and III, neither turbid solution nor
oil drop was observed. Sample appearance was normal and
the propofol contents was still greater than or equal to 90%
(≧90%).
For studied samples stored within CRYOVAC®
non-PVC bags at ambient temperature and under light condition for 15 days, propofol samples went turbid and developed
a pale-yellow color as shown in Table 4. In addition, it was
easy to observe small oil drops in sample solution. After
remixing by shaking, the propofol content was less than 90%.
For samples under condition II (in the dark and at ambient
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Table 4. Propofol (%) in different solution after 8 and 15 days storage
Day8

Day15

Glass CRYOVAC®

glass

CRYOVAC®

94.99a

80.61c

Propofol MCT/LCT 2 mg/mL
Ambient light and

95.29a

temperature
Dark and ambient

92.27b
b

80.61c

90.11b

77.69c

92.27
96.31a

temperature

97.73a
95.96

96.80a

a

89.79c

96.22a
Dark and at 2-8°C

a

96.17

95.92

a

87.01c
96.74

a

98.09a
95.41

90.79a

95.29a
102.17a

a

96.31a

Propofol MCT/LCT 2.5 mg/mL
Ambient light and

98.55a

temperature
Dark and ambient

90.70b

temperature

93.73b

85.16c

95.40a
96.24

98.67a

a

Dark and at 2-8°C

99.78

94.57

a

89.97c
90.07a

91.33a
a

83.59c
81.30c

88.19
99.78a

100.71a

b

17.16d
96.17

a

94.05a

93.53a

94.68a

94.57a

91.23a

a

The sample solution shows white uniform solution phase and
contained no yellow oil drop. The propofol content is greater than or
equal to 90% (≧ 90%).
b
The sample solution shows white cloudy accompany with some oil
droplets. After shaking, the oil droplets will disappear. The propofol
content is greater than or equal to 90% (≧ 90%).
c
The sample solution shows light-yellow cloudy accompany with
many oil droplets. The propofol content is less than 90% (< 90%).
d
The sample solution is emulsified and layered seriously. The
propofol content is less than detection limit.

permeability to water vapor and O2, thus inducing instability
of propofol emulsions. CRYOVAC® non-PVC bag compared
to glass may slightly accelerate permeability to water vapor
and O2, especially at high temperature. This could be one
reason using glass bottle as the container for a better stability
since glass bottle was more impermeable than non-PVC bag.
However, the variations in concentration were too slight for
them to have any clinical impact. In this study, the decrease
in propofol concentration started to occur only after 15 days
storage at room temperature in non-PVC bag, well beyond
the usual storage time in clinical practice. By avoiding light
exposure and stored at 2-8°C, it is possible to place the
propofol emulsion in non-PVC soft bag over 2 weeks.
Intravenously administered fat droplets exceeding
5 μm in diameter are believed to cause adverse reactions, in
particular emboli in the lungs. Now that new particle detection techniques have emerged, new requirements for the
limitation of particle sizes in intravenous fat emulsions have
to be established. It would seem logical that next to the mean
particle size requirement, also limitations be specified for the
particle size distribution. Special attention should be paid to
the number of large particles and the upper size limit. Each
requirement should include the techniques and methods to
be used.
IV. Analysis of DEHP in the Propofol MCT/LCT Solution
Non-PVC products may contain much smaller amounts
of DEHP. Flexible PVC-free products still must be tested
to ascertain whether they are in fact DEHP-free. No DEHP
was detected in each solution of propofol MCT/LCT in
CRYOVAC® after 15 days storage under any of the temperature and light conditions tested. The limit of quantification
for DEHP by this chromatography method was  5 ppm of
solution of propofol MCT/LCT in 0.9% NaCl solution.

CONCLUSIONS
temperature), similar results were obtained. One sample
showed an extremely low propofol content, i.e. 17%, due
to phase separation and very poor recovery after remixing.
Interestingly, for samples stored and in the dark and at 2-8°C
for 15 days, neither appearance change nor significant content
change was observed, indicating that propofol emulsion in
CRYOVAC® non-PVC bags was stable when stored at 2-8°C
and in the dark for 15 days.
It was found the propofol samples went turbid at day
8 and worse at day 15. This phenomenon was alleviated by
placing the samples in the dark. This suggested that propofol
sample is sensitive to light exposure. It is likely that light
exposure in the presence of residual oxygen is the major
factor that resulted in the decrease of propofol content. In
addition, propofol contents were different between solutions stored at room temperature and at 2-8°C after 15
days storage, suggesting temperature is another factor for
the propofol stability. High temperature may accelerate
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In the present study, propofol MCT/LCT emulsion in
0.9% NaCl solutions were stored at three different conditions
for 5 days and up to two weeks. Appearance of solution and
propofol content were assayed to determine the stability of
studied samples. According to the analytical results listed in
Table 2 and Table 3, the propofol emulsion in non-PVC soft
bag was stable for 5 days when stored at ambient tempearture
and in the light, at ambient tempearture and in the dark, and
at 2-8°C in the dark. For long term storage, propofol emulsion in CRYOVAC® non-PVC soft bag was stable for 15 days
when stored at 2-8°C in the dark.
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